MSH2 and metastatic prostate carcinoma: Another study compared the prevalence of pathogenic/likely pathogenic germline variants in Black and White men with metastatic prostate cancer and found that Black men were more likely to have a germline BRCA1 mutation and were less likely to have a non-BRCA DNA repair germline variant (as defined by MSH2, MSH6, PMS2, MLH1,ATM, RAD50, RAD51D, NBN, CHEK2, BRIP1, PALB2, RAD51C, ATM, BLM, and TP53) [35].